Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06070636 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

StatusUnknown
PhaseNot applicable
Started2024-05-20
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 9, 2024 (before its estimated January 30, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06
Trial status changed: Recruiting → Unknown
2024-08-08
Study Status v2
Trial statusRecruiting→Unknown
2024-05-16
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Completion date2025-12-30→2025-06-30
Start date2023-10-01→2024-05-20
Study sitesdetails revised at 1 of 1 site
2023-09-30
Original filing
This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and Camrelizumab for patients with infiltrative hepatocellular carcinoma.
Trial Details
NCT Number NCT06070636
Lead Sponsor Sun Yat-sen University
Conditions Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Lenvatinib, Sintilimab
Enrollment 30 participants
Start Date 2024-05-20
Primary Completion 2025-01-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-08-09